Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2
Mark Jordan Althoff, Mohd Minhajuddin, Brett M. Stevens, Austin E. Gillen, Stephanie Gipson, Sweta B. Patel, Ian T. Shelton, Regan Miller, Ana Vujovic, Anna Krug, Tracy Young, William M. Showers, Monika Dzieciątkowska, Daniel Stephenson, Anit Tyagi, , Craig T. Jordan
This study identifies IRF2BP2 cytoplasmic sequestration by MCL1 as a mechanism driving venetoclax and azacitidine resistance in AML through ACSL1 derepression.
bioRxiv · May 22, 2025 · PreprintCancer Biology